Biosignatures of Chronic Drug Exposure (R21)

The summary for the Biosignatures of Chronic Drug Exposure (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Biosignatures of Chronic Drug Exposure (R21): -Purpose. In relation to this FOA, biosignatures are defined as biological indicators obtainable through assays, which can be used to ascertain facts about an individual's past exposure to drugs of abuse. Biosignature could be comprised of more than one biomarker. The total number of biomarkers must be reasonably limited to address the developability of the screening assay. This FOA would support high risk projects to search for peripheral, not associated with the central nervous system, biosignatures (not drug or drug metabolites) that could serve as surrogates to monitor changes that are taking place in the brain in response to illicit and licit drug exposure, withdrawal or relapse. These projects are intended to be feasibility projects using animal models only to identify appropriate clinically accessible biomaterial (e.g., blood, lymphocytes, bladder epithelial cells, stem cells) and to identify the best class or classes of molecules (proteins, peptides, RNA, miRNA, etc.) suitable for assay development . These feasibility projects are intended to address technical issues such as sensitivity and signal-to-noise ratio, in addition to predictive validity. . -Mechanism of Support. This FOA will utilize the R21 grant mechanism, as The National Institute on Drug Abuse recognizes the high risk nature of this project. -Funds Available and Anticipated Number of Awards. The total amount of funding that the NIDA expects to award through this announcement is $2,000,000 for an anticipated 5-7 awards.
Federal Grant Title: Biosignatures of Chronic Drug Exposure (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-09-022
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse and Addiction Research Programs
Current Application Deadline: Jan 27, 2009
Original Application Deadline: Jan 27, 2009
Posted Date: Oct 01, 2008
Creation Date: Oct 01, 2008
Archive Date: Feb 27, 2009
Total Program Funding: $2,000,000
Maximum Federal Grant Award: $200,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - C...
Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not ...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical ...
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Mino...
Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowe...
NINDS Program Project Grant (P01 Clinical Trial Optional)
Centers for Research in Emerging Infectious Diseases (CREID) Network (U01 Clinical Trial N...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com